



ICG-001

Catalog No: tcsc0273

Available Sizes
Size: 5mg
Size: 10mg
Size: 50mg
Size: 100mg
Specifications
CAS No: 780757-88-2
Formula: C ₃₃ H ₃₂ N ₄ O ₄
Pathway: Stem Cell/Wnt
Target: Wnt
Purity / Grade: >98%
Solubility: H2O:
Observed Molecular Weight: 548.63

Product Description

ICG-001 is an antagonist of Wnt/β -catenin/TCF-mediated transcription and specifically binds to element-binding protein (CBP) with IC_{50}





of 3 μ M.

IC50 & Target: IC50: 3 µM (CBP)

In Vitro: ICG-001 (5µM) inhibits leptin-induced EMT, invasion and tumorsphere formation in MCF7 cells^[1]. ICG-001 can phenotypically rescue normal nerve growth factor (NGF)-induced neuronal differentiation and neurite outgrowth in the presentin-1 mutant cells, emphasizing the importance of the TCF/ β -catenin signaling pathway on neurite outgrowth and neuronal differentiation ^[2]. ICG-001 (25µM) treatment reduces the steady-state levels of Survivin and Cyclin D1 RNA and protein in SW480 cells, both of which can be up-regulated by β -catenin. ICG-001 selectively induces apoptosis in transformed cells but not in normal colon cells, and reduces in vitro growth of colon carcinoma cells^[3].

In Vivo: ICG-001 (5 mg/kg per day) significantly inhibits beta-catenin signaling and attenuates bleomycin-induced lung fibrosis in mice, while concurrently preserving the epithelium^[2]. Administration of a water-soluble analog of ICG-001 for 9 weeks reduces the formation of colon and small intestinal polyps by 42% as effectively as the nonsteroidal antiinflammatory agent Sulindac, which has consistently demonstrated efficacy in this model. ICG-001 (150 mg/kg, i.v.) demonstrates a dramatic reduction in tumor volume over the 19-day course of treatment, with no mortality or weight loss in the SW620 nude mouse xenograft model of tumor regression^[3].

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!